Limes Schlosskliniken AG (DE:LIK)
XETRA:LIK
Want to see DE:LIK full AI Analyst Report?
Top Page
Limes Schlosskliniken AG
(XETRA:LIK)
Select Model
Select Model
Rating:74Outperform
Price Target:
€558.00
▲(55.00% Upside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by solid financial performance (growth and profitability with a strengthening balance sheet), tempered by uneven free cash flow and margin volatility. Technicals are supportive with an uptrend across moving averages and positive MACD, while valuation is helped by a low P/E.
Positive Factors
Sustained Revenue Growth
The company has shown durable top-line expansion with 2025 revenue ~19% above 2024 and multiyear strength noted in 2022–2025. Persistent organic growth supports scale, broadens referral networks, and underpins longer-term investments in facilities and specialist services.
Negative Factors
Uneven Free Cash Flow
Volatile free cash flow and weak cash conversion in select years constrain the firm's ability to reliably self-fund growth, return capital, or absorb shocks. Recurrent FCF swings suggest working-capital or reinvestment timing risks that complicate multi-quarter planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
The company has shown durable top-line expansion with 2025 revenue ~19% above 2024 and multiyear strength noted in 2022–2025. Persistent organic growth supports scale, broadens referral networks, and underpins longer-term investments in facilities and specialist services.
Read all positive factors
Limes Schlosskliniken AG (LIK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€151.50M
Dividend YieldN/A
Average Volume (3M)37.00
Price to Earnings (P/E)18.5
Beta (1Y)-0.06
Revenue Growth33.49%
EPS Growth81.79%
CountryDE
Employees210
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)19.29
Shares Outstanding300,000
10 Day Avg. Volume27
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)4.17
Price to Sales (P/S)2.11
P/FCF Ratio142.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.98
Revenue Forecast (FY)€66.40M
Limes Schlosskliniken AG Business Overview & Revenue Model
Company Description
LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, ...
How the Company Makes Money
null...
Limes Schlosskliniken AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.00M | 37.45M | 37.17M | 28.81M | 23.43M |
| Gross Profit | 19.06M | 34.50M | 16.23M | 10.82M | 8.37M |
| EBITDA | 12.79M | 7.05M | 7.67M | 8.65M | 6.02M |
| Net Income | 5.69M | 3.11M | 3.40M | 4.20M | 3.94M |
Balance Sheet | |||||
| Total Assets | 45.17M | 38.56M | 33.25M | 26.65M | 18.44M |
| Cash, Cash Equivalents and Short-Term Investments | 10.31M | 10.88M | 8.52M | 10.93M | 2.48M |
| Total Debt | 10.73M | 10.48M | 10.09M | 9.04M | 4.33M |
| Total Liabilities | 18.35M | 18.72M | 16.61M | 15.45M | 12.13M |
| Stockholders Equity | 25.31M | 18.33M | 15.13M | 11.10M | 6.31M |
Cash Flow | |||||
| Free Cash Flow | 740.24K | 2.48M | -3.51M | 6.35M | -1.83M |
| Operating Cash Flow | 9.38M | 7.46M | 6.29M | 7.70M | 4.55M |
| Investing Cash Flow | -8.63M | -4.96M | -9.79M | -1.31M | -6.38M |
| Financing Cash Flow | -1.25M | -159.15K | 1.09M | 2.04M | 1.40M |
Limes Schlosskliniken AG Technical Analysis
Positive
360.00
Price Trends
490.16
Positive
458.63
Positive
407.99
Positive
Market Momentum
4.92
Negative
61.88
Neutral
86.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:LIK, the sentiment is Positive. The current price of 360 is below the 20-day moving average (MA) of 489.20, below the 50-day MA of 490.16, and below the 200-day MA of 407.99, indicating a bullish trend. The MACD of 4.92 indicates Negative momentum. The RSI at 61.88 is Neutral, neither overbought nor oversold. The STOCH value of 86.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:LIK.
Limes Schlosskliniken AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €362.35M | 6.07 | 15.83% | 2.80% | 6.52% | 7.17% | |
74 Outperform | €151.50M | 18.52 | 22.77% | ― | 33.49% | 81.79% | |
65 Neutral | €169.10M | 116.46 | 10.71% | 1.12% | 5.13% | 11.89% | |
63 Neutral | €21.63B | 14.29 | 7.76% | 2.05% | 4.22% | 248.36% | |
57 Neutral | €843.42M | 16.32 | 3.04% | 0.77% | 6.06% | 0.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | €20.76M | -1.54 | 23.56% | ― | 3.51% | -5.66% |
* Healthcare Sector Average
DE:LIK
Limes Schlosskliniken AG
505.00
207.00
69.46%
DE:FRE
Fresenius SE & Co. KGaA
39.21
-3.11
-7.34%
DE:MED
MEDICLIN
3.52
0.66
23.08%
DE:RHK
RHON-KLINIKUM AG
12.70
-0.39
-2.99%
DE:MAK
MATERNUS-Kliniken AG
1.01
-0.54
-34.84%
DE:M12
M1 Kliniken AG
18.76
4.64
32.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.